Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Sacramento, California and other locations
Dates
study started
completion around

Description

Summary

This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). CB-839 HCl and sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Official Title

A Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Advanced NSCLC Patients

Details

Keywords

Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Carcinoma, Lung Neoplasms, Neoplasms, Non-Small-Cell Lung Carcinoma, Meningeal Neoplasms, Sapanisertib, Telaglenastat Hydrochloride

Eligibility

Locations

  • University of California Davis Comprehensive Cancer Center
    Sacramento California 95817 United States
  • Keck Medicine of USC Koreatown
    Los Angeles California 90020 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT04250545
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 85 study participants
Last Updated